Groundbreaking Rutgers Discovery: Low-Protein Diets Target Ammonia to Curb Liver Cancer
A pioneering study from Rutgers Cancer Institute has illuminated a potential dietary strategy to combat one of the deadliest cancers: hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Researchers led by Wei-Xing Zong, a distinguished professor at Rutgers Ernest Mario School of Pharmacy, demonstrated that restricting dietary protein significantly slows tumor growth and extends survival in preclinical models by addressing a critical metabolic vulnerability—ammonia accumulation. This finding challenges conventional nutrition advice for cancer patients and opens new avenues for preventive nutrition in at-risk populations.
The research, published in Science Advances on January 29, 2026, underscores how everyday protein consumption contributes to cancer risk when liver function is compromised—a scenario increasingly common amid rising rates of non-alcoholic fatty liver disease (NAFLD) and cirrhosis. As liver cancer claims nearly 31,000 lives annually in the United States, this work from Rutgers highlights the power of simple interventions grounded in metabolic science.
The Alarming Rise of Liver Cancer in the US
Liver cancer incidence has tripled in the US over the past four decades, with an estimated 42,340 new cases and 30,980 deaths projected for 2026, according to the American Cancer Society (ACS). The age-adjusted incidence rate stands at 9.4 per 100,000, disproportionately affecting men (13.1 per 100,000) and certain demographics like Hispanic/Latino (14.1) and American Indian/Alaska Native populations (18.7). Five-year survival remains dismal at 22%, improving only to 38% for localized cases, emphasizing the urgency for preventive measures.
Risk factors include chronic hepatitis B and C viruses (HBV/HCV), excessive alcohol, obesity, type 2 diabetes, and NAFLD, which affects up to 25% of Americans. These conditions impair liver function, setting the stage for malignant transformation. Rutgers researchers posit that dietary protein exacerbates this vulnerability by fueling ammonia buildup, a toxin the damaged liver struggles to detoxify.
Ammonia's Toxic Role in Liver Metabolism Explained
Ammonia (NH3), a byproduct of dietary protein breakdown—primarily by gut microbes—is normally detoxified in the liver via the urea cycle. This multi-enzyme process (urea cycle enzymes, or UCEs, such as carbamoyl phosphate synthetase 1 [CPS1]) converts ammonia into urea for urinary excretion. In healthy livers, this safeguards against toxicity; however, in diseased livers, UCE expression is repressed, leading to hyperammonemia.
Excess ammonia doesn't just poison cells; it serves as a nitrogen source for glutamine and nucleotide synthesis, essential for rapid tumor proliferation. Rutgers findings reveal ammonia also activates mechanistic target of rapamycin complex 1 (mTORC1), a key nutrient sensor pathway that drives cancer cell growth, protein synthesis, and survival. Step-by-step: Protein → gut fermentation → ammonia → portal vein to liver → impaired urea cycle → systemic/hyperlocal ammonia → mTORC1 hyperactivation → HCC progression.
- Healthy scenario: Efficient urea cycle prevents buildup.
- Pathological: UCE mutations (common in 20-30% HCC cases) amplify risk.
Human HCC tumors show downregulated UCEs, correlating with poor prognosis—a pattern Rutgers causally linked to tumorigenesis.
Rutgers Mouse Models Uncover Causal Evidence
To test causality, Rutgers scientists used multiple HCC models: diethylnitrosamine (DEN)-induced tumors, STAM (NAFLD-mimicking), and gene-edited mice lacking key UCEs like CPS1. Tumors were induced without initial ammonia defects, then UCEs disrupted via CRISPR.
Results were striking: Ammonia-elevated mice developed heavier tumors (2-3x burden) and died sooner. Switching to low-protein diet (6-7% kcal from protein vs. 20% standard) slashed ammonia levels by 50-70%, halted mTORC1 activation, reduced tumor mass by 60-80%, and doubled median survival.
"Reducing protein consumption may be the easiest way to get ammonia levels down," notes Zong. These models mimic human NAFLD-cirrhosis-HCC progression, validating translational potential.
Photo by Nigel Hoare on Unsplash
Decoding the Ammonia-mTORC1 Axis in Cancer Cells
Mechanistically, ammonia acts as a nitrogen donor: NH3 + glutamate → glutamine (via glutamine synthetase), fueling nucleotide biosynthesis and anaplerosis for tricarboxylic acid (TCA) cycle. Critically, glutamine-derived alpha-ketoglutarate senses ammonia as nutrient, phosphorylating/activating mTORC1—promoting anabolic growth.
Low-protein diets interrupt upstream: Less undigested protein reaches colon → fewer ammonia-producing bacteria → portal ammonia drops → less mTORC1 fuel. Prior studies link mTORC1 hyperactivation to HCC; inhibitors like rapamycin show promise but face toxicity. Dietary restriction offers a non-pharmacologic adjunct.
| Factor | Standard Protein | Low Protein |
|---|---|---|
| Ammonia Levels | High | Low |
| mTORC1 Activity | Hyperactive | Inhibited |
| Tumor Burden | High | Reduced 60-80% |
| Survival | Short | Doubled |
This table summarizes Rutgers' key contrasts in DEN and STAM models.
Read the full Rutgers study in Science AdvancesRelevance to High-Risk Groups: NAFLD and Cirrhosis Patients
Over 100 million Americans have NAFLD, 20% progressing to non-alcoholic steatohepatitis (NASH) with fibrosis/cirrhosis—precancerous states. Rutgers data suggest low-protein diets could stratify prevention: Monitor serum ammonia; if elevated, restrict protein to 0.8g/kg body weight (vs. RDA 1.2g/kg for liver disease).
Stakeholders like hepatologists advocate personalized nutrition. For Rutgers researchers pioneering this, explore higher ed jobs in cancer metabolism at leading US universities.
Supporting Evidence from Broader Protein Restriction Research
Protein restriction's anti-cancer effects predate Rutgers: Mouse studies show 50% protein cut inhibits mTORC1, shrinks tumors synergistically with immunotherapy. Caloric/protein restriction reprograms tumor-associated macrophages, enhances T-cell function. Human trials sparse but promising: Low-protein diets improve NAFLD histology, reduce IGF-1 (mTOR activator).
- Benefits: Metabolic stress sensitizes cancer cells to therapy.
- Risks: Muscle loss in cachectic patients—monitor sarcopenia.
- Comparisons: Keto (low-carb) vs. low-protein: Latter targets ammonia specifically.
Integrate with ACS guidelines: Balance protein for maintenance while minimizing excess.Career advice for nutrition researchers.
Rutgers press releaseExpert Perspectives and Clinical Cautions
"The ammonia-handling impairment in liver cancer patients is decades old; we proved it's causal," says Zong. Oncologists caution: Standard care boosts protein for cachexia, but Rutgers paradigm shifts to ammonia phenotyping first. No ongoing trials yet (as of March 2026), but calls for RCTs in NAFLD cohorts.
Multi-perspective: Dietitians emphasize plant-based low-protein (legumes, veggies) over animal sources (higher ammonia yield). Rutgers positions as trusted hub; rate professors via Rate My Professor.
Future Directions: From Bench to Clinic
Prospects: Ammonia-lowering drugs (e.g., L-ornithine) + diet; biomarkers for patient selection. Rutgers plans human studies. Broader implications: mTORC1 modulation via nutrition for other cancers. US universities drive this; seek university jobs in oncology research.
Actionable Insights for At-Risk Individuals
Consult MD before changes. Sample low-protein day: Breakfast oats/fruit (10g protein), lunch veggie stir-fry/tofu (15g), dinner quinoa salad/fish portion (20g)—total ~50g for 70kg adult. Track ammonia via blood tests. Future: Personalized via Rutgers-inspired genomics.
For academics advancing this field, faculty positions abound. Explore career advice, rate courses at Rate My Professor, find higher ed jobs.